profit from every $100 of sales.
$0$100
Jazz Pharmaceuticals
$240.37-3.17% today
+75.8% in 1 year
1-year low $136.711-year high $261.62
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Jazz Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $3.66 billion in 2022 to $4.27 billion in 2025, with -$356 million of profit last year.
SalesProfit
Jazz Pharmaceuticals handed back 11% of the cash it generated last year.
Buybacks $125M
Free cash flow 2025$1.1B
Bought back its own shares$125M
Paid as dividends–
Cash vs. debt$1.4B vs. $5.4B
Jazz Pharmaceuticals vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Jazz Pharmaceuticals | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads Jazz Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 2,364 | 3,094 | 3,659 | 3,834 | 4,069 | 4,268 | |
| – | – | 3,119 | 3,399 | 3,623 | 3,764 | |
| – | – | 512 | 598 | 727 | 518 | |
| 656 | 723 | 545 | 1,226 | 1,369 | 263 | |
| 239 | -330 | -224 | 415 | 560 | -356 | |
| 4.22 | -5.52 | -3.58 | 6.10 | 8.65 | -5.84 | |
| – | – | 85.2% | 88.6% | 89.0% | 88.2% | |
| – | – | 14.0% | 15.6% | 17.9% | 12.1% | |
| 10.1% | -10.7% | -6.1% | 10.8% | 13.8% | -8.3% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 6,536 | 12,299 | 10,835 | 11,393 | 12,012 | 11,659 |
| Cash | 1,058 | 591 | 881 | 1,506 | 2,413 | 1,392 |
| Total debt | 2,095 | 6,050 | 5,812 | 5,792 | 6,162 | 5,424 |
| Total liabilities | – | – | 7,750 | 7,656 | 7,919 | 7,341 |
| 3,660 | 3,965 | 3,086 | 3,737 | 4,094 | 4,319 | |
| 57 | 60 | 63 | 72 | 66 | 61 | |
| 5.2% | 1.3% | -0.8% | 4.9% | 5.5% | -3.5% | |
| 6.5% | -8.3% | -7.3% | 11.1% | 13.7% | -8.2% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 900 | 779 | 1,272 | 1,092 | 1,396 | 1,356 | |
| – | – | 498 | 43 | 48 | 210 | |
| – | – | 774 | 1,049 | 1,348 | 1,146 | |
| Dividends paid | – | – | – | – | – | – |
| 147 | 0 | 0 | 270 | 311 | 125 | |
| 121 | 189 | 222 | 227 | 248 | 291 |
Valuation
- –
- 10.0×
- –
- 3.3×
- 3.6×
- 13.5×
- 73.9×
- 7.4%
- -2.3%
- 0.0%
Profitability
- 88.2%
- 12.1%
- -8.3%
- 8.9%
- -0.6%
- 0.1%
- 0.7%
- 0.2%
- 5.1%
- 16.6%
Growth
- +12.5%
- –
- −3.8%
- –
- +0.5%
Financial health
- 9.0×
- 1.20
- 45.7%
- 2.4×
- 2.04
- 1.85
- 0.37
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 34%of 952
Top 43%of 883
Top 45%of 870
Top 11%of 985
What analysts expect
- Average price target
- $216.14
- Range
- $188.00 – $235.00
- 3 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | 6.34 | 4.67 | +35.8% |
| Feb 24, 2026 | 6.64 | 6.52 | +1.8% |
| Nov 5, 2025 | 8.13 | 5.95 | +36.6% |
| Aug 5, 2025 | -8.25 | -6.12 | −34.8% |
| May 6, 2025 | 1.68 | 4.51 | −62.7% |
| Feb 25, 2025 | 6.60 | 5.83 | +13.2% |
| Nov 6, 2024 | 6.61 | 5.47 | +20.8% |
| Jul 31, 2024 | 5.30 | 4.68 | +13.2% |
News
Where Will Jazz Pharmaceuticals Be in 5 Years? Oncology Is Becoming Its Growth EngineYahoo Finance · Oct 27, 2026Jazz Pharmaceuticals sees $755M IPR&D charge in Q3 resultsSeeking Alpha · Oct 26, 20262 Reasons to Avoid JAZZ and 1 Stock to Buy InsteadYahoo Finance · Sep 11, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
33No pass
Benjamin Graham
26No pass
Philip Fisher
41No pass
Peter Lynch
41No pass
Joel Greenblatt
2No pass
Charlie Munger
27No pass
Terry Smith
28No pass
Questions about Jazz Pharmaceuticals
Is Jazz Pharmaceuticals a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Jazz Pharmaceuticals AI analysis
What does Jazz Pharmaceuticals do?
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. It is in Biotechnology, based in Dublin, Ireland, with 2,890 employees.
Does Jazz Pharmaceuticals pay a dividend?
No. Jazz Pharmaceuticals does not pay a dividend at the moment; in 2025 it returned $125 million to shareholders by buying back its own shares.
Is Jazz Pharmaceuticals stock halal?
No. Jazz Pharmaceuticals does not pass our halal screen: its debt is 35% of its market value, at or above the 33% limit. How we check
How has Jazz Pharmaceuticals stock done over the past year?
Up 75.8% over the past twelve months, to $240.37. It traded between $136.71 and $261.62 and is 8.1% below its high.
Who are Jazz Pharmaceuticals's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Jazz Pharmaceuticals's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.